Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.95 USD
Change Today -0.10 / -1.65%
Volume 10.1M
EXEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Exelixis, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net product revenues of $7,992,000 compared to $6,562,000 a year ago. Loss from operations was $31,280,000 compared to $61,688,000 a year ago. Net loss was $43,362,000 or $0.22 per basic and diluted share compared to $73,410,000 or $0.38 per basic and diluted share a year ago. The decreased net loss for the quarter was primarily due to decreases in research and development expenses and selling, general and administrative expenses and an increase in product revenues. For the six months period, the company reported net product revenues of $17,380,000 compared to $11,467,000 a year ago. Loss from operations was $54,040,000 compared to $126,676,000 a year ago. Net loss was $78,532,000 or $0.40 per basic and diluted share compared to $148,029,000 or $0.77 per basic and diluted share a year ago.

Exelixis, Inc. to Report Q2, 2015 Results on Aug 11, 2015

Exelixis, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 11, 2015

Exelixis, Inc., Q2 2015 Earnings Call, Aug 11, 2015

Exelixis, Inc., Q2 2015 Earnings Call, Aug 11, 2015

Exelixis, Inc. - Special Call

To discuss positive top-line results from the primary analysis of METEOR

Exelixis, Inc. Announces Executive Changes

Exelixis, Inc. announced the appointment of Christopher J. Senner as Executive Vice President and Chief Financial Officer. In this role, Mr. Senner will oversee the company’s global finance function, leveraging extensive experience gained earlier in his career. Mr. Senner has nearly 25 years of experience in biopharmaceutical finance, including deep expertise in global financial operations and controls, strategic planning and analysis, supply chain finance and business development. He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. Mr. Senner will succeed Deborah Burke, who has served as Senior Vice President and Chief Financial Officer since September 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $5.95 USD -0.10

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.44 USD -0.45
Array BioPharma Inc $5.90 USD -0.04
Curis Inc $2.62 USD +0.03
Cytokinetics Inc $6.92 USD -0.08
Evotec AG €3.76 EUR -0.018
View Industry Companies
 

Industry Analysis

EXEL

Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.